跳至主要内容
临床试验/EUCTR2018-004604-20-BE
EUCTR2018-004604-20-BE进行中(未招募)1 期

Myo-inositol versus clomiphene citrate as first line treatment for ovulation induction in PCOS

Ghent University Hospital0 个研究点目标入组 320 人开始时间: 2019年10月14日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
320

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
Female

入选标准

  • Rotterdam criteria for PCOS (cf. the recent ESHRE guidelines): at least 2 out of 3 criteria should be fulfilled:
  • -irregular cycle (shorter than 21 days or longer than 35 days);
  • -clinical (modified Ferriman-Gallwey score = 6) or biochemical signs (elevated free testosterone) of hyperandrogenism (www.eshre.eu/Guidelines-and-Legal/Guidelines/Polycystic-Ovary-Syndrome.aspx);
  • -PCO ovaries on ultrasound (www.eshre.eu/Guidelines-and-Legal/Guidelines/Polycystic-Ovary-Syndrome.aspx): multiple small cysts (= 20 per ovary and/or an ovarion volume = 10 ml, measured with a probe >8 MHz) in both ovaries.
  • Age: 18 until 40 years old (extremes included).
  • A first treatment cycle, possibly combined with intra uterine insemination (IUI) and this for (one of) the following reasons:
  • -mild male factor (as defined by each local center)
  • -endometriosis AFS score 1 or 2
  • Use of own or donor sperm.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 320
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • -Tubal factors
  • -Uterine factors
  • -Endometriosis AFS score 3 or 4
  • -Moderate to severe male factor (as defined by each local center)
  • -BMI > 35

研究者

相似试验